Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR ...
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR ...
1. The median overall survival was similar between both groups, 15.2 months in atezolizumab monotherapy vs 13.3 months in chemotherapy, ...
Click to read the study in The Lancet ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.